Replication in Medical Technology
Navigation Links
Replication in Medical Technology
... understanding of the protein chemistry of rapid replication enables us to develop synthetic vaccines specifically tailored to destroy or restrict replication of the targeted virus strains prior to an ... a new group of peptides related to the rapid replication function in viral and other diseases. The company ...
... of JX-594 was validated in patients by demonstration of tumor-specific replication and tissue destruction with JX-594, in addition to high-level active ... novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously ...
... cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this ...
... patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation). PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and ...
... patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation). PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and ...
... differentiated adult neural stem cells for the cellular restoration and treatment of Parkinson's disease. Our original methodology is based on the replication of several steps in human neurogenesis to regenerate millions of mature neurons characterized before transplantation. These steps are essential to ...
... underway, three REOLYSIN(R) trials are now being sponsored by our collaborators." The primary objectives of the trial are to assess the presence, replication and anti-cancer effects of reovirus within liver metastases after intravenous administration of REOLYSIN(R) by examination of the resected tumour. ...
... studies have demonstrated the potential for once per day dosing and a high safety margin for the compound. IQP-0410 has been found to inhibit HIV replication at sub-nanomolar concentration levels and to have highly significant activity against all clinical virus strains evaluated as well as against ...
... agent, is currently approved in oral form as 5mg, 20mg, 100mg, 140mg, 180mg and 250mg capsules in Europe. Cytotoxic agents are designed to impact the replication of cells that divide rapidly, such as those in tumors. TEMODAL was initially approved in the European Union (EU) in 1999 for the treatment of ...
... many patients in the right situation." The MitraClip device creates a double orifice mitral valve by securing the leaflets to reduce MR in a replication of the surgical procedure pioneered by Ottavio Alfieri, MD. The resulting double orifice has an inherently smaller cross sectional area compared to ...
... patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation). PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is ...
... cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this ...
... provides funding for the continued development of the dual-acting pyrimidinedione molecules which effectively inhibit two critical steps in the HIV replication pathway important for a microbicide. The research to be performed will enable ImQuest scientist's to comparatively evaluate their most potent lead ...
... Lenexa, Kan., is eligible for a $420,000 convertible note to support the development of its therapeutic vaccine for HIV designed to inhibit viral replication by enhancing antibody and cellular immune response. The KBA investment will help the company secure an equal amount of funds from other sources. -- ...
... These data demonstrate potent antiviral activity and a favorable safety profile at all tested doses. "The profound inhibition of HIV-1 virus replication of IDX899 at doses of 400 and 200 mg daily confirm the potent antiviral activity previously reported at higher doses," said Dr. Robert Murphy, John ....
... profile to Synagis(R) (palivizumab) in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract. In its pivotal clinical trial, which was a head-to-head comparative trial with Synagis, motavizumab demonstrated ...
... the clinical observations of Genetic Immunity's founders. Their examination of the "Berlin Patient" proved that induction of immune control of HIV replication is feasible in an infected patient. The Company has developed the DermaVir Patch to induce the immune system to kill HIV infected cells specifically ...
... cancer programs, as well as the patients and researchers from 15 academic medical centers in Europe and the United States who took part in the replication of the discovery published today. How to order deCODE PrCa(TM) deCODE PrCa(TM) is performed in deCODE's Clinical Laboratory Improvement ...
... treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a NNRTI and other ARV agents. This indication is based on Week 24 analyses from two randomized, double- blind, ...
... humans that average at least 10-fold higher than the serum-adjusted EC50. "This level of exposure over the concentration of drug needed to inhibit replication of the virus by 50% supports the potential for promising antiviral activity of our drug in HIV-infected patients who are naive to antiretroviral ...
Replidyne Provides Strategic Update
... difficile-associated disease (CDAD), and its DNA replication inhibition program. As a result of ... REP3123 in the second half of 2008. About DNA replication Inhibition DNA replication is one of the essential steps in bacterial growth ...Clinical Update - Debio 025 in Hepatitis C
... Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication advantage to HCV. Its potent inhibitory activity on the HCV replication was shown in the following clinical studies. Results of a phase Ib study ...Clinical Update - Debio 025 in Hepatitis C
... Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication advantage to HCV. Its potent inhibitory activity on the HCV replication was shown in the following preclinical and clinical studies. Results of a ...... of JX-594 was validated in patients by demonstration of tumor-specific replication and tissue destruction with JX-594, in addition to high-level active ... novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously ...
Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
... of JX-594 was validated in patients by demonstration of tumor-specific replication and tissue destruction with JX- 594, in addition to high-level ... novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously ...Clinical Update - Debio 025 in Hepatitis C
... Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication advantage to HCV. Its potent inhibitory activity on the HCV replication was shown in preclinical studies. Previous results of a phase Ib study ...Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
... (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be ... works by inhibiting protease, an enzyme needed to complete the HIV replication process. The approved dose of APTIVUS is 500 mg taken with 200 mg of ...Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
... to stage two, in which the enrollment target is an additional 105 patients. Unlike other classes of HIV drugs that work to inhibit viral replication within human CD4+ cells, most of which are part of the immune system, vicriviroc is an HIV entry inhibitor designed to prevent the virus from ...Gene Findings Unlocking Reasons for Neuroblastoma Risk
... Medicine. Scientists from six other centers in addition to Children's Hospital and the University of Pennsylvania contributed to the discovery or replication of the findings. Capasso et al, "Common variations in BARD1 influence susceptibility to high-risk neuroblastoma," Nature Genetics , ...... cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this ...
FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications
... Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey replication (NCS-R). Archives of General Psychiatry, 2005 Jun;62(6):617-27. (8) Mauricio Tohen et al. (2007). Olanzapine versus Placebo in the Treatment of ...IBM and EU Partners Create a Better Way to Fight AIDS Virus
... HIV genetic variant. EuResist is a powerful online system that helps doctors choose the treatment with the highest probability of halting virus replication and impairing evolution of drug resistance. Although there have been tremendous leaps and bounds in the management of the virus that causes ...Autism Genes Discovered; Help Shape Connections Among Brain Cells
... Foundation. Scientists from 14 other centers in addition to Children's Hospital and the University of Pennsylvania contributed to the discovery or replication of the findings. Wang et al, "Common genetic variants on 5p14.1 associate with autism spectrum disorders," Nature , published online April 28, ...... patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation). PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and ...
... patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation). PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and ...
... differentiated adult neural stem cells for the cellular restoration and treatment of Parkinson's disease. Our original methodology is based on the replication of several steps in human neurogenesis to regenerate millions of mature neurons characterized before transplantation. These steps are essential to ...
... underway, three REOLYSIN(R) trials are now being sponsored by our collaborators." The primary objectives of the trial are to assess the presence, replication and anti-cancer effects of reovirus within liver metastases after intravenous administration of REOLYSIN(R) by examination of the resected tumour. ...
Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
... cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this ...... studies have demonstrated the potential for once per day dosing and a high safety margin for the compound. IQP-0410 has been found to inhibit HIV replication at sub-nanomolar concentration levels and to have highly significant activity against all clinical virus strains evaluated as well as against ...
... agent, is currently approved in oral form as 5mg, 20mg, 100mg, 140mg, 180mg and 250mg capsules in Europe. Cytotoxic agents are designed to impact the replication of cells that divide rapidly, such as those in tumors. TEMODAL was initially approved in the European Union (EU) in 1999 for the treatment of ...
... many patients in the right situation." The MitraClip device creates a double orifice mitral valve by securing the leaflets to reduce MR in a replication of the surgical procedure pioneered by Ottavio Alfieri, MD. The resulting double orifice has an inherently smaller cross sectional area compared to ...
... patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation). PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is ...
... cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this ...
New Bisphenol A Study Has Limited Capability to Assess Human Health Effects
... useful for generating hypotheses that can be tested with more appropriate experiments or analyses. As noted by the authors of the study, independent replication and follow-up studies are needed to confirm their findings and to provide evidence on whether the associations are causal. Until such work has been ...... provides funding for the continued development of the dual-acting pyrimidinedione molecules which effectively inhibit two critical steps in the HIV replication pathway important for a microbicide. The research to be performed will enable ImQuest scientist's to comparatively evaluate their most potent lead ...
... Lenexa, Kan., is eligible for a $420,000 convertible note to support the development of its therapeutic vaccine for HIV designed to inhibit viral replication by enhancing antibody and cellular immune response. The KBA investment will help the company secure an equal amount of funds from other sources. -- ...
... These data demonstrate potent antiviral activity and a favorable safety profile at all tested doses. "The profound inhibition of HIV-1 virus replication of IDX899 at doses of 400 and 200 mg daily confirm the potent antiviral activity previously reported at higher doses," said Dr. Robert Murphy, John ....
Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
... About ANA598 ANA598 is a highly potent and selective inhibitor of HCV genotypes 1a and 1b NS5b RNA polymerases (IC50 < 1 nM) and of HCV replication in cell culture (EC50 values for genotypes 1b and 1a replicons are 3 and 50 nM, respectively). ANA598 has been well-tolerated in all preclinical ...PEGASYS(R)/COPEGUS(R) Show Benefit in Hard-to-Treat Latino Population with Hepatitis C
... patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation). PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is ...... profile to Synagis(R) (palivizumab) in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract. In its pivotal clinical trial, which was a head-to-head comparative trial with Synagis, motavizumab demonstrated ...
Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
... of the virus replikin concentration increases. Replikins are peptides, specified in virus genomes, which increase in concentration signaling rapid replication before virus outbreaks. This is the first report that cyclic increases in virus replikin concentration, each apparently building on the last, can be ...Replidyne Discontinues Phase III Trial
... bacteria and C. difficile- associated disease (CDAD). Replidyne is pursuing the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research. Safe Harbor This press release contains plans, intentions, objectives, estimates and ...Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
... the antiviral effect of subsequent treatment with interferon (8-fold decrease in concentration of interferon required to inhibit virus replication by 90%). "Data presented in each of these communications has provided important information in guiding the ongoing clinical development of ...AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
... to the volunteers at two dosage levels. A key design and safety feature of this single-cycle vaccine technology is that there is no further replication of the virus-like particles after the expression of the CMV proteins in the vaccine recipients. About CMV CMV is a herpesvirus that is a major ...Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
... product insert for information on this product. 4 Vicriviroc, a next generation CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment-experienced adults: VICTOR-E1 48-week results (39LB); 15th Conference on Retroviruses and Opportunistic Infections (CROI); ...... the clinical observations of Genetic Immunity's founders. Their examination of the "Berlin Patient" proved that induction of immune control of HIV replication is feasible in an infected patient. The Company has developed the DermaVir Patch to induce the immune system to kill HIV infected cells specifically ...
... cancer programs, as well as the patients and researchers from 15 academic medical centers in Europe and the United States who took part in the replication of the discovery published today. How to order deCODE PrCa(TM) deCODE PrCa(TM) is performed in deCODE's Clinical Laboratory Improvement ...
... treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a NNRTI and other ARV agents. This indication is based on Week 24 analyses from two randomized, double- blind, ...
... humans that average at least 10-fold higher than the serum-adjusted EC50. "This level of exposure over the concentration of drug needed to inhibit replication of the virus by 50% supports the potential for promising antiviral activity of our drug in HIV-infected patients who are naive to antiretroviral ...
Other Contentsmeristemmesodermeraeraeraeraeraeramessagemessagemessagemessagemessagemessagemessagemessagemessagemetacentricmetazoamethylationmethylationmethylationmethylationmethylation
Breaking Biology News(10 mins):Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4Jatropha Couple Oil Crop Cultivation Technology Commercially Released 13320 1Jatropha Couple Oil Crop Cultivation Technology Commercially Released 13320 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 13320 3Innovator 26apos 3Bs Studio offers Social Media Strategy Intensive Sept 16 17 2009 53443 1Innovator 26apos 3Bs Studio offers Social Media Strategy Intensive Sept 16 17 2009 53443 2Innovator 26apos 3Bs Studio offers Social Media Strategy Intensive Sept 16 17 2009 53443 3Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 1Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 2Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 3Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 4Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 5
Breaking Medicine News(10 mins):Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 2Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 3Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 4Health News:City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans 5Health News:Lilly Announces the First 300-unit Vial of Insulin 2Health News:Lilly Announces the First 300-unit Vial of Insulin 3Health News:Lilly Announces the First 300-unit Vial of Insulin 4Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 2Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 3Health News:Prostate Hormone Therapy May Up Heart Risks 2Health News:Prostate Hormone Therapy May Up Heart Risks 3Health News:New approach to sickle-cell disease shows promise in mice 2
Other TagsFlaskNovagencerevisiaecerevisiaestainingLoopAphAphAphAphAphAphAphAphMutMutMutMutMutMutOther Tagsdementia 2victims 2victims 3disaster 2dating 2[0] City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans[0] Lilly Announces the First 300-unit Vial of Insulin[0] Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health[0] Prostate Hormone Therapy May Up Heart Risks[1] New approach to sickle-cell disease shows promise in mice
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |